Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Denali Therapeutics Inc (Denali Therapeutics) is a biotechnology company that focuses on developing a broad portfolio of drug candidates for neurodegenerative diseases. Its pipeline products include DNL310 for MPS II (hunter syndrome), BIIB122/DNL151 for parkinson's, and TAK-594/DNL593 for frontotemporal dementia-granulin; DNL126 for MPS IIIA (sanfilippo syndrome); DNL622 for MPS I; and eclitasertib (SAR443122/DNL758) for systemic inflammation (UC). The company's products are designed for patients suffering from neurodegenerative conditions, with applications in the healthcare and pharmaceutical industries. It leverages TransportVehicle platform for drug development. Denali Therapeutics is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
161 Oyster Point Blvd., South San Francisco, California, 94080
Website
www.denalitherapeutics.com
Telephone
1 650 8668547
No of Employees
507
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DNLI (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-21.2%
(2024 vs 2023)
Market Cap*
$3.8B
Net Profit Margin (2022)
XYZ
85.4%
(2024 vs 2023)
* As of and is in US$
Denali Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | TransportVehicle |
| Lysosomal Function: | |
| DNL310: MPS II (Hunter Syndrome) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In January, the company received a grant breakthrough therapy designation from the US Food and Drug Administration for tividenofusp alfa (DNL310) to treat individuals with Hunter syndrome (MPS II). |
| 2022 | Official Trials/Tests | In May, the company and Biogen Inc announced the initiation of phase 2b study of LRRK2 inhibitor in Parkinson’s disease. |
| 2022 | Others | In May, the company and Sanofi commenced dosing in a Phase 2 study, HIMALAYA of SAR443820 (DNL788) in individuals with amyotrophic lateral sclerosis (ALS). |
Competitor Comparison
| Key Parameters | Denali Therapeutics Inc | Eli Lilly and Co | Biogen Inc | Eisai Inc | Ionis Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | Indianapolis | Cambridge | Nutley | Carlsbad |
| State/Province | California | Indiana | Massachusetts | New Jersey | California |
| No. of Employees | 507 | 50,605 | 7,500 | 832 | 1,402 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Julian Baker | Chairman | Executive Board | 2025 | 59 |
| Ryan J. Watts, Ph.D | Chief Executive Officer; President; Director | Executive Board | 2015 | 50 |
| Cindy Dunkle | Chief People Officer | Senior Management | - | - |
| Peter Chin, MD | Head - Development; Chief Medical Officer | Senior Management | 2026 | 58 |
| Joe Lewcock, Ph.D | Chief Scientific Officer | Senior Management | 2016 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer